Patents Issued in April 11, 2024
  • Publication number: 20240115615
    Abstract: Modified stem cells and methods of use for stem cell transplant are provided.
    Type: Application
    Filed: February 9, 2022
    Publication date: April 11, 2024
    Inventors: Wendy PANG, Judith SHIZURU, Robert SIKORSKI, Rajiv TIWARI, Hye-Sook KWON
  • Publication number: 20240115616
    Abstract: The present disclosure provides a method for treating liver cirrhosis by using a composition including mesenchymal stem cells, extracellular vesicles produced by the mesenchymal stem cells, and growth factors. The composition of the present disclosure achieves the effect of treating liver cirrhosis through various efficacy experiments.
    Type: Application
    Filed: October 4, 2023
    Publication date: April 11, 2024
    Inventors: Po-Cheng Lin, Pi-Chun Huang, Zih-Han Hong, Ming-Hsi Chuang, Yi-Chun Lin, Chia-Hsin Lee, Chun-Hung Chen, Chao-Liang Chang, Kai-Ling Zhang
  • Publication number: 20240115617
    Abstract: The invention provides compositions for establishing mixed chimerism in a subject. The compositions include CD34+ cells and CD3+ cells derived from an apheresis product obtained from a subject that has previously donated a solid organ. The invention also provides methods of making and using such compositions.
    Type: Application
    Filed: October 18, 2023
    Publication date: April 11, 2024
    Inventor: Steven R. Deitcher
  • Publication number: 20240115618
    Abstract: The present disclosure provides a method for treating or preventing endothelial dysfunction in a subject, the method comprising systemically administering to the subject a population of population of cells enriched for STRO-1+ cells and/or progeny thereof and/or soluble factors derived therefrom.
    Type: Application
    Filed: October 4, 2023
    Publication date: April 11, 2024
    Inventors: Wayne Gregory Kimpton, Simon Reeves Bailey, Silviu Itescu, Peter Ghosh
  • Publication number: 20240115619
    Abstract: Disclosed are novel means of enhancing efficacy of pancreatic islet transplantation through administration of regenerative T cells concurrently with modification of the local microenvironment to provide a tolerogenic and angiogenic milieu. In one embodiment, the liver microenvironment is prepared for receipt of pancreatic islets by administration of tolerogenic cells antigen presenting cells, subsequently followed by administration of T cells and/or T regulatory cells conditioned by regenerative cells, and finally pancreatic islets are administered. In other embodiments devices are provided which allow for concurrent administration of pancreatic islets together with T cells and/or T regulatory cells that have been conditioned with regenerative cells. In another embodiment, the administration of T cells and/or T regulatory cells conditioned by regenerative cells is after administration of therapeutic pancreatic islets.
    Type: Application
    Filed: October 9, 2023
    Publication date: April 11, 2024
    Applicant: CREATIVE MEDICAL TECHNOLOGIES, INC.
    Inventors: Thomas ICHIM, Amit PATEL, Courtney BARTLETT, Timothy WARBINGTON
  • Publication number: 20240115620
    Abstract: The present disclosure provides methods, compositions, and systems for producing and using organoids comprising fibroblasts. The organoids can be generated and placed in a particular storage matrix which allows for sufficient conditions for transport and reduces damage to cells in the organoids compared to known media. The organoids may be utilized for extended release of the fibroblasts for cell therapy and also for drug delivery at a target site following administration to an individual in need thereof.
    Type: Application
    Filed: October 9, 2023
    Publication date: April 11, 2024
    Inventors: Bin JIANG, Hamid KHOJA, Pete O'HEERON
  • Publication number: 20240115621
    Abstract: The present application is directed to the field of implants comprising soft tissue for use in implantation in humans. The soft tissue implants of the present application are preferably obtained from xenograft sources. The present application provides a chemical process that sterilizes, removes antigens from and/or strengthens xenograft implants. The present techniques yield soft tissue implants having superior structural, mechanical, and/or biochemical integrity. The present application is also directed to processes for treating xenograft implants comprising soft tissues such as dermis, and to implants produced by such processes.
    Type: Application
    Filed: December 20, 2023
    Publication date: April 11, 2024
    Applicant: Tutogen Medical GmbH
    Inventors: Arnd Wilhelmi, Silke Schreiner, Jake Michaelson, Steven Moore, Jennifer Faleris, Anne Reinlein
  • Publication number: 20240115622
    Abstract: A novel formulation for the prevention and treatment of COVID-19 is disclosed, featuring the antiviral properties of xylitol and bee propolis. These natural compounds were tested against porcine coronavirus (PEDV), human OC43 virus, and SARS-CoV-2. Notably, propolis and xylitol showed protective effects at concentrations below cytotoxic levels. The formulation is presented as a dental product with propolis (0.25-2.00 wt. %) and xylitol (0.25-3.0 wt. %) alongside various agents for oral and nasal applications. These findings suggest a promising approach to combat coronaviruses and provide an inventive solution for COVID-19 prevention and treatment.
    Type: Application
    Filed: October 6, 2023
    Publication date: April 11, 2024
    Inventor: Jacques Veronneau
  • Publication number: 20240115623
    Abstract: A method of expanding a complex community of microorganisms is provided, an expanded complex community of microorganisms obtained by the method is provided, a pharmaceutical formulation comprising the expanded complex community of microorganisms is provided, and the use of the expanded complex community of microorganisms and the pharmaceutical formulation is provided.
    Type: Application
    Filed: December 23, 2021
    Publication date: April 11, 2024
    Inventors: Hervé AFFAGARD, Carole SCHWINTNER, Cécile VERDIER, Sylvain DENIS, Jean-François BRUGERE, Monique ALRIC
  • Publication number: 20240115624
    Abstract: A method for treating an inflammatory skin disease, including administering to a subject in need thereof a pharmaceutical composition containing Ruminococcus gnavus as an active ingredient. A method for treating an inflammatory skin disease, including applying to a subject in need thereof a cosmetic composition containing Ruminococcus gnavus as an active ingredient.
    Type: Application
    Filed: October 6, 2023
    Publication date: April 11, 2024
    Applicants: THE ASAN FOUNDATION, UNIVERSITY OF ULSAN FOUNDATION FOR INDUSTRY COOPERATION
    Inventor: Soo-Jong HONG
  • Publication number: 20240115625
    Abstract: The disclosure relates to live biotherapeutic products, probiotics, pharmaceutical compositions comprising said probiotics, and methods of using them to treat various human diseases. In some aspects, the disclosure provides such compositions comprising strains of the bacteria Rosburia hominis and Eubacterium eligens and their uses in treating metabolic-related diseases or disorders.
    Type: Application
    Filed: February 21, 2023
    Publication date: April 11, 2024
    Inventors: Andrew Wonhee Han, Andrew Whitman Goodyear, Mitsuko Lynn Yamamoto, Todd Zachary DeSantis, Karim Dabbagh
  • Publication number: 20240115626
    Abstract: Compositions and methods for converting at least one glucosinolate to an isothiocyanate using Bacillus subtilis 839, Bacillus subtilis CO4_4, Pediococcus pentosaceus M3_H01, and/or Pediococcus pentosaceus M2_H12, or active variants thereof, are provided. Conversion of glucosinolates, such as glucoraphanin, to isothiocyanates, such as sulforaphane, leads to the stimulation of the Nrf2/Keap pathway and phase II enzymes, providing chemoprotective and anti-inflammatory effects. Accordingly, provided herein are compositions comprising Bacillus subtilis 839, Bacillus subtilis CO4_4, Pediococcus pentosaceus M3_H01, and/or Pediococcus pentosaceus M2_H12, or active variants thereof, for administration to subjects for increasing isothiocyanate (e.g., sulforaphane) production, increasing the expression of genes regulated by the Nrf2 transcription factor, including phase II enzymes, decreasing inflammation, and treating or preventing an inflammatory disorder or a cancer.
    Type: Application
    Filed: September 14, 2023
    Publication date: April 11, 2024
    Applicant: Church & Dwight Co., Inc.
    Inventors: Noah Paul Zimmerman, Amy Wescott
  • Publication number: 20240115627
    Abstract: The present disclosure relates to use of a Clostridium ghonii spore combined with pembrolizumab in cancer treatment. It is found for the first time that the Clostridium ghonii spore combined with pembrolizumab can significantly improve a curative effect of colon cancer and reduce a dose of the pembrolizumab, and thus is efficient and low-toxic. Oncolysis by Clostridium ghonii can affect immunogenicity of a tumor microenvironment (TME) by various ways, converts an immunosuppressive state of the TME into an immune-activated state, adjusts the immunosuppressive TME, and breaks an immune tolerance. An optimal combination of the Clostridium ghonii spore and the pembrolizumab thoroughly removes about 20% of mouse tumor tissues. A benefit range of patients with tumors treated by a PD-1 antibody is expanded. The combination even has an obvious curative effect on patients failed the treatment by the PD-1 antibody.
    Type: Application
    Filed: October 9, 2022
    Publication date: April 11, 2024
    Inventors: Yong Wang, Hong Zhu, Wenhua Zhang, Yanqiu Xing, Dan Wang, Yuanyuan Liu, Shaopeng Wang, Jiahui Zheng, Rong Zhang, Xiaonan Li, Xinglu Xu, Shengbiao Jiang, Lichao Xing, Yuxia Gao, Shili Shao, Ting Han
  • Publication number: 20240115628
    Abstract: The present invention relates to a composition comprising a Leuconostoc citreum strain or a culture thereof as an active ingredient for preventing, improving or treating fibrosis, specifically pulmonary fibrosis, renal fibrosis or hepatic fibrosis. According to the present invention, since the composition exhibits excellent preventive and therapeutic effects on various fibrosis, the composition may be usefully used as a composition for the treatment, prevention, improvement, or the like of fibrosis in humans or animals.
    Type: Application
    Filed: February 7, 2022
    Publication date: April 11, 2024
    Applicant: LISCURE BIOSCIENCES CO., LTD.
    Inventor: Hwa Sup CHIN
  • Publication number: 20240115629
    Abstract: Described herein is an oral composition, such as a toothgel or a toothpaste, comprising Streptococcus salivarius, a viscosity modifier, a buffering agent, and a non-aqueous carrier. Advantageously, the oral composition may provide a desirable property, including a delayed release profile of the probiotic, improved colonisation in an oral cavity of a subject, improved stability and/or improved syneresis.
    Type: Application
    Filed: February 14, 2022
    Publication date: April 11, 2024
    Inventors: John David Francis HALE, Rohit JAIN
  • Publication number: 20240115630
    Abstract: This invention relates to the use of a bacterium of the genus Bifidobacterium, particularly, but not exclusively, a bacterium of the Bifidobacterium animalis ssp. lactis strain 420 (B420) for use in reducing food, energy and/or fat intake.
    Type: Application
    Filed: May 15, 2023
    Publication date: April 11, 2024
    Inventors: Lotta Stenman, Sampo Lahtinen
  • Publication number: 20240115631
    Abstract: The present invention relates to a composition for relieving hangover, the composition comprising the grain-derived lactic acid bacterium strain Lactobacillus fermentum JS (accession number/KCCM-10499) which exhibits a potential of increasing enzymatic activity of alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH), and to a composite lactic acid bacterium composition for relieving hangover, the composition comprising the seven lactic acid bacterium species Lactobacillus plantarum, Lctobacillus casei, Lactobacillus rhamnosus, Lactobacillus acidophilus, Lactococcus lactis, Bifidobacterium breve, and Bifidobacterium lactis, which, although low in the potential of increasing enzymatic activity of ADH and ALDH, exhibits synergy effects when used in combination with the grain-derived lactic acid bacterium strain Lactobacillus fermentum JS (accession number/KCCM-10499).
    Type: Application
    Filed: October 11, 2019
    Publication date: April 11, 2024
    Applicant: WELL-BEING LS CO., LTD
    Inventors: Jong Soon PARK, Dong Jin LEE, Deuk Sik LEE
  • Publication number: 20240115632
    Abstract: A method for preventing or treating a metabolic disease includes administering to an individual a composition comprising at least one of a Lactobacillus plantarum-derived polysaccharide or and a Lactobacillus plantarum extract. The metabolic disease may be metabolic disease is at least one selected from the group consisting of insulin resistance, type 2 diabetes, hyperlipidemia, fatty liver, obesity and/or inflammation.
    Type: Application
    Filed: February 4, 2022
    Publication date: April 11, 2024
    Inventors: Jeong Min SEO, Jae Hoon LEE
  • Publication number: 20240115633
    Abstract: The present invention relates to a composition for the nutrition or drink of a non-human animal comprising the combination of spirulina and Ascophyllum nodosum. It further relates to the use of this composition for improving the zootechnical performance of non-human animals, in order to reduce the emission of greenhouse gases, in particular methane, in a non-human mammal, in order to increase the digestibility of the dry matter and fibers, in particular forage and concentrates, and/or to improve the consumption index and/or the dietary efficiency and/or to promote weight gain and/or to increase the intensity of fermentation and of microbial metabolism and/or to inhibit flora protozoa and/or to reduce the degradation of proteins and/or to orient the fermentation towards the production of volatile fatty acids in a non-human mammal, in order to improve the quality of the meat and/or the growth performance and/or the well-being of a non-human animal.
    Type: Application
    Filed: February 7, 2022
    Publication date: April 11, 2024
    Inventors: Anca L. LAZA KNOERR, Sandra POINT, Auriane DE TONNAC, Philippe DUMARGUE
  • Publication number: 20240115634
    Abstract: An object of the invention is to provide a composition for improving memory learning function and/or cognitive function or suppressing deterioration thereof which can be orally taken daily and continuously. As a result of intensive studies, the present inventors have found that the object can be achieved with a composition for improving memory learning function and/or cognitive function or suppressing deterioration thereof containing at least one kind selected from the group consisting of spirulina, phycocyanin, enzymatically degraded spirulina and enzymatically degraded phycocyanin as an active ingredient.
    Type: Application
    Filed: January 20, 2022
    Publication date: April 11, 2024
    Applicant: DIC Corporation
    Inventors: Yasuyuki Imai, Yurino Koseki
  • Publication number: 20240115635
    Abstract: An agent is described that includes a plant virus particle or VLP conjugate to TRAIL. Associating TRAIL with the plant virus particle or VLP serves to both target cancer cells and induce their apoptosis. The agent can therefore be used for a method of treating cancer in a subject.
    Type: Application
    Filed: June 13, 2023
    Publication date: April 11, 2024
    Inventor: Nicole F. Steinmetz
  • Publication number: 20240115636
    Abstract: The present disclosure relates to recombinant RNA molecules encoding an oncolytic virus genome. The present disclosure further relates to the encapsulation of the recombinant RNA molecules and the use of the recombinant RNA molecules and/or particles for the treatment and prevention of cancer.
    Type: Application
    Filed: January 6, 2022
    Publication date: April 11, 2024
    Inventors: Lorena LERNER, Edward M. KENNEDY, Christophe QUÉVA, Jessica DETERLING, Jeffrey David BRYANT, Qi-Ying HU, Tooba A. CHEEMA, Sean ESSEX
  • Publication number: 20240115637
    Abstract: A natural based therapeutic compound which helps alleviate inflammation, pain, and/or discomfort caused by disease and injuries, as well as can be used in palliative and/or hospice care includes honey, THC-9 distillate, and powdered Psilocybe cubensis.
    Type: Application
    Filed: May 2, 2023
    Publication date: April 11, 2024
    Inventor: Glenn Edward Adams
  • Publication number: 20240115638
    Abstract: The present technology is directed towards providing an apparatus, system and method for the cost-effective extraction of compounds of interest, such as CBD and THC, from freshly harvested cannabis plant material. The system includes a processing module with a tank that has a flow path to a separator. The tanks are filled with a cooling agent and cannabis plant material which is immersed and agitated to break up the plant material. The filtered outflow from the tank is a filtrate of a mixture of cooling agent and broken up plant material that is transferred to the separator to separate out at least some trichomes containing the compounds of interest.
    Type: Application
    Filed: December 24, 2021
    Publication date: April 11, 2024
    Inventor: Greg Charles MISSON
  • Publication number: 20240115639
    Abstract: The present invention provides for a method for obtaining an oil extract of cannabis. The method includes: (a) contacting cannabis biomass and an edible oil; (b) pressing between a pair of plates to provide spent cannabis and an oil extract of cannabis; and (c) separating the spent cannabis biomass and the oil extract of cannabis.
    Type: Application
    Filed: December 18, 2023
    Publication date: April 11, 2024
    Inventors: Toby W. Laughton, Darren J. Nist, Steven M. Shatkin, Tony LaRosa, David Reid
  • Publication number: 20240115640
    Abstract: A method for preparing ginseng extract rich in rare ginsenosides is disclosed. Ginseng roots or ginseng stems and leaves are extracted, enzymatically hydrolyzed and treated with high temperature and high pressure. The preparation method can quickly and effectively increase the proportion of rare ginsenosides in the ginseng extract. After in vitro antioxidant experiments and in vivo experiments with Hidradenitis elegans nematode, the extract and related complexes were proved to be effective in antioxidant, anti-oxidative stress, and improving age-related muscle decline and other dysfunctions. After genetic and metabolomic studies, the anti-aging mechanism was proved to be related to the expression of genes associated with nutrient sensing, stress-related pathways and redox processes, and showed innate immune response and redox process GO enrichment, proving its oxidative stress resistance.
    Type: Application
    Filed: December 19, 2023
    Publication date: April 11, 2024
    Inventors: Shengcan Zou, Dongli Yin, Jinli Chen, Jinli Liu, Decui Yin, Haijun Zhang
  • Publication number: 20240115641
    Abstract: Disclosed are an oral film and stick jelly containing glutathione and a milk thistle extract. Provided are an oral disintegrating film, an oral mucosal adhesive film, and a stick jelly that contain glutathione, a milk thistle extract, or the like as an active ingredient, and thus are highly efficacious in improving absorption in the oral mucosa, antioxidant activity, and anti-inflammatory activity, strengthening immunity, and enhancing liver function of humans and companion animals.
    Type: Application
    Filed: February 17, 2022
    Publication date: April 11, 2024
    Applicants: ESTHER FORMULA CO., LTD., BIO360 CO., LTD
    Inventors: Esther LYUH, Kun Se KIM, Eun Soo SUH, Byoung Hag KIM, Mi Young AN, Dae Seong CHEON, Jae Hun KIM, Young Jae PARK, Byeong Hyeon KIM, Hyo Seon CHOI
  • Publication number: 20240115642
    Abstract: The present invention relates to a composition for preventing hair loss or promoting hair growth containing a milk thistle flower extract as an active ingredient. More specifically, the present invention relates to a cosmetic composition, pharmaceutical composition and food composition containing a milk thistle flower extract as an active ingredient, which are able to promote hair growth by inducing the proliferation of dermal papilla cells reduced due to senescence, and activate dermal papilla cells by inhibiting the senescence of dermal papilla cells through inhibition of the activity of senescence-associated ?-galactosidase (SA-?-Gal) and the production of senescence-associated secretory phenotypes, thereby preventing hair loss or promoting hair.
    Type: Application
    Filed: August 18, 2022
    Publication date: April 11, 2024
    Inventors: Ji Eun WOO, Seoung Woo SHIN, Eun Sun JUNG, Deok Hoon PARK
  • Publication number: 20240115643
    Abstract: Topical compositions formulated for application to the skin, methods of preparing the topical compositions, and methods of administering the topical composition to a subject are described. The compositions can include one or more components selected from a Moringa oleifera extract, ceramide, free fatty acid, sterol, and silk. The method includes administering the topical composition to a subject to treat a skin disorder such as radiation dermatitis or erythema.
    Type: Application
    Filed: October 10, 2023
    Publication date: April 11, 2024
    Inventor: Nancy Franklin
  • Publication number: 20240115644
    Abstract: The present invention is a pharmaceutical or food composition comprising a pretreated extract and an isolate and an isolated and purified product of Cinnamomum cassia showing a pharmacological effect. It relates to an active ingredient showing physiological activity in the Cinnamomum cassia extract.
    Type: Application
    Filed: December 23, 2021
    Publication date: April 11, 2024
    Inventors: Shin Jung PARK, Yunyoung LIM, Hyo Jun KIM, Bo Hee HONG, Yun Sik KIM
  • Publication number: 20240115645
    Abstract: Provided in the present invention is a pharmaceutically active ingredient extract extracted from Polygala japonica Houtt., which extract comprises a flavonol compound of the following formula (I) structure as a first active ingredient, and optionally comprises a xanthone compound selected from the following formula (II) as a second active ingredient and a glycolipid compound selected from the following formula (III-1) as a third active ingredient. An animal experiment confirms that the drug of the present invention has significantly better effects than potassium sodium hydrogen citrate in typical test indicators such as calcium oxalate crystal aggregation, renal interstitial inflammatory cell infiltration and renal tubule dilation lesions, showing that the drug has high potential and market prospects in the treatment of urolithiasis and urinary tract infections or kidney damage caused by urolithiasis, and as an adjuvant drug after surgical treatment of urolithiasis.
    Type: Application
    Filed: December 29, 2021
    Publication date: April 11, 2024
    Applicant: HONG ZHANG
    Inventor: HONG ZHANG
  • Publication number: 20240115646
    Abstract: A composition comprises about 1% to 5% by weight of apple cider vinegar; a gellant; about 1% to 10% by weight ascorbic acid; a sweetener; and water.
    Type: Application
    Filed: October 11, 2022
    Publication date: April 11, 2024
    Inventors: Nadine Aubourg, Kamala Arango
  • Publication number: 20240115647
    Abstract: The present invention relates to a composition comprising the association of the molecules of flavanol monomers and ?-viniferin as a nutritional product or a drug for humans or animals.
    Type: Application
    Filed: September 27, 2021
    Publication date: April 11, 2024
    Inventors: David GAUDOUT, Stéphane REY, Benoit LEMAIRE, Line POURTAU, Camille POUCHIEU, Séverine DUBREUIL, Benjamin MORAS, Mégane BORNERIE, Julien GABASTON, Manon ROLAIT, Astrid DE VULPILLIERES
  • Publication number: 20240115648
    Abstract: Hydrophilic Linkers, Drug-Linker compounds, Drug-Ligand Conjugate compounds and Ligand-Linkers and methods of making and using the same are provided.
    Type: Application
    Filed: July 28, 2023
    Publication date: April 11, 2024
    Inventors: Svetlana DORONINA, Robert LYON, Peter SENTER
  • Publication number: 20240115649
    Abstract: The present invention relates to the field of caspase inhibition. More specifically, the present invention provides compositions and methods utilizing caspase inhibitors to enhance injury repair and to treat bacterial and viral infections. In a specific embodiment, a method for treating a bacterial infection and skin lesions in a patient comprises the step of administering to the patient an effective amount of a caspase inhibitor.
    Type: Application
    Filed: September 29, 2023
    Publication date: April 11, 2024
    Inventors: Luis Garza, Mohameed Islam
  • Publication number: 20240115650
    Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: December 11, 2023
    Publication date: April 11, 2024
    Applicant: ABBVIE INC.
    Inventors: Walid M. Awni, Barry M. Bernstein, Andrew L. Campbell, Sandeep Dutta, Chih-Wei Lin, Wei Liu, Rajeev M. Menon, Thomas J. Podsadecki, Tianli Wang, Sven Mensing
  • Publication number: 20240115651
    Abstract: Methods and materials for treating and preventing autoimmune diseases, in particular, multiple sclerosis (MS) including small peptides are capable of interacting with CD40, thereby altering and/or modulating the ability of CD40 to interact with CD154, which apparently affects inflammation; and/or the use of such peptides in reducing the inflammatory response, and in particular, the autoimmune inflammatory response; and/or the use of such short peptides to prevent or reverse autoimmune disease, and particularly, multiple sclerosis, in individuals; and/or methods and materials for detecting T-cells that express CD40 (Th40 cells). Also provided are kits for reducing inflammation, treating autoimmune diseases, or detecting Th40 cells. Additionally, methods and apparatuses to administer the peptide are provided.
    Type: Application
    Filed: September 14, 2023
    Publication date: April 11, 2024
    Inventors: David Hal Wagner, JR., Martin Glenn Yussman, Charles W. Henry, Gisela M. Vaitaitis
  • Publication number: 20240115652
    Abstract: There is provided a bioabsorbable peptide tissue occluding agent that can be applied to large mammals including humans, the peptide tissue occluding agent being obtained by artificial synthesis to avoid concerns of infection by viruses and the like. The tissue occluding agent contains a peptide, wherein the peptide is an amphiphilic peptide having 8-200 amino acid residues with the hydrophilic amino acids and hydrophobic amino acids alternately bonded, and is a self-assembling peptide exhibiting a ?-structure in aqueous solution in the presence of physiological pH and/or a cation.
    Type: Application
    Filed: September 13, 2023
    Publication date: April 11, 2024
    Inventors: Kentaro Takamura, Satoshi Gojo, Satoru Kobayashi
  • Publication number: 20240115653
    Abstract: The invention provides a method and kits for inhibiting integrin ?9?1 activity comprising contacting integrin ?9?1 or a binding partner of integrin ?9?1 with an isolated anti-integrin ?9 inhibitor, wherein the integrin ?9?1 activity is inhibited. In certain aspects, the present invention provides a novel intervention by targeting integrin ?9?1 with a functional blocking inhibitor (e.g., peptides or antibodies) to limit brain damage following reperfusion after ischemic stroke.
    Type: Application
    Filed: October 13, 2023
    Publication date: April 11, 2024
    Applicant: UNIVERSITY OF IOWA RESEARCH FOUNDATION
    Inventors: Anil K. Chauhan, Nirav A. Dhanesha
  • Publication number: 20240115654
    Abstract: Disclosed herein are peptides with antimicrobial, antiviral, antifungal or antitumor activity when administered to a subject. Also disclosed herein are methods that can be used for treating or preventing a condition or disease in a human subject in need thereof comprising intravenously administering a pharmaceutical composition to said human subject over an extended period of time.
    Type: Application
    Filed: August 10, 2023
    Publication date: April 11, 2024
    Inventors: Jonathan D. STECKBECK, David HUANG, Despina X. DOBBINS
  • Publication number: 20240115655
    Abstract: In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to treat a complement-mediated disorder, e.g.
    Type: Application
    Filed: February 28, 2023
    Publication date: April 11, 2024
    Inventors: Federico Grossi, Pascal Deschatelets, Cedric Francois, Patrick Johnson, Carolina Vega
  • Publication number: 20240115656
    Abstract: The invention provides methods for treating a patient with constipation-predominant irritable bowel syndrome by administering a therapeutically effective dose of linaclotide.
    Type: Application
    Filed: December 15, 2023
    Publication date: April 11, 2024
    Inventors: Jeffrey Johnston, Bernard Joseph Lavins, Harvey Schneier
  • Publication number: 20240115657
    Abstract: A composition comprises a water-soluble polymer matrix in which are dispersed droplets of oil, the composition comprising an active principle. The invention includes embodiments in which the active principle is included in at least some of the oil droplets as well as embodiments in which the oil droplets are released as the matrix containing them dissolves in an aqueous medium. In one embodiment, the oil droplets are substantially immobilized in or by the matrix and the immobilizing feature is lost as the matrix dissolves in aqueous media. In certain embodiments, the oil drops may collectively be referred to as the oil phase of the composition of the invention. The product may be in the form of mini-beads. The oil phase and/or the polymer matrix may each include a surfactant.
    Type: Application
    Filed: April 19, 2023
    Publication date: April 11, 2024
    Applicant: Sublimity Therapeutics Limited
    Inventors: Ivan Coulter, Bernard Francis McDonald, Vincenzo Aversa
  • Publication number: 20240115658
    Abstract: A use of an intervertebral disc fibrosis-inducing substance in preparation of medication, where the medication is used for the treatment of degenerative spinal diseases. The inventors of the present disclosure make use of the pro-fibrotic effect of the intervertebral disc fibrosis-inducing substance and the auxiliary effect of the fibroblast to achieve further treatment of intervertebral disc degeneration. The simultaneous administration of the above two drugs can reasonably control the degeneration and achieve the purpose of stepped treatment, thereby having clinical transformation value. In addition, the therapy combining the intervertebral disc fibrosis-inducing substance with the cell in the present disclosure allows the treatment regimen more personalized.
    Type: Application
    Filed: June 11, 2021
    Publication date: April 11, 2024
    Applicant: Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine
    Inventors: Jie ZHAO, Chen CHEN, Xiao YANG, Tangjun ZHOU, An QIN, Zhiqian CHEN, Kai ZHANG, Yifan ZHOU
  • Publication number: 20240115659
    Abstract: Both Sp2CBMTD and Vc2CBMTD were shown to reduce the apical viral load of RSV-infected human airway epithelial cells. The degree of reduction was dependent on the type of mCBM and number of doses administered. Exposure of infected MucilAlr inserts to Sp2CBMTD did not show a significant effect on viral replication due to variability of data but a slight reduction was observed at the highest dose (100 ?g) after two doses at 48 h p.i (see FIG. 23A), and after three doses at 96 h p.i. compared to virus infected control. Exposure to Vc2CBMTD (100 ?g) was more effective in reducing RSV viral replication in both dosing regimens than using a 10 ?g dosing regimen. Although not statistically significant, the reduction of viral load at 48 h p.i was observed to decreased greater than 1 log (FIG. 23B).
    Type: Application
    Filed: October 12, 2023
    Publication date: April 11, 2024
    Inventors: Helen Connaris, Lei Yang, Jane Alexandra Potter
  • Publication number: 20240115660
    Abstract: The present invention relates to a composition for preventing or treating heart failure including TREM2 protein or a fragment thereof as an active ingredient. The TREM2 protein or fragment thereof according to the present invention can be prepared as a soluble form and used as an injection, and when injected into the body, it promotes functional and structural improvement of the infarcted heart, and is effective for preventing or treating heart failure, and more specifically, it can be advantageously used for preventing or treating heart failure that appears as a sequela of myocardial infarction.
    Type: Application
    Filed: April 10, 2023
    Publication date: April 11, 2024
    Inventors: Yeun-Jun CHUNG, Kiyuk CHANG, Seung-Hyun JUNG, Eunhye PARK
  • Publication number: 20240115661
    Abstract: Provided herein are methods of treating, preventing, and managing metabolic or cardiovascular disorders and methods of reducing cardiovascular risk with FGF21 protein variants, including Fc-FGF21 variant fusion proteins.
    Type: Application
    Filed: July 26, 2023
    Publication date: April 11, 2024
    Inventors: Allison GOLDFINE, Byungdoo Alexander YI
  • Publication number: 20240115662
    Abstract: Described herein are methods of inducing cognitive recovery of a subject suffering from a traumatic brain injury (TBI). The methods comprise administering to the subject pharmaceutical compositions including human chorionic gonadotropic (hCG) and/or luteinizing hormone (hLH), or a combination thereof.
    Type: Application
    Filed: March 2, 2022
    Publication date: April 11, 2024
    Inventor: Craig S. ATWOOD
  • Publication number: 20240115663
    Abstract: A composition for treating diabetes, in particular type 1 diabetes, in a patient/person having a BMI of more than 28, in particular of more than or equal to 30 and/or an HbA1c of more than 7.6%, includes an insulin and an amylin receptor agonist. The composition can be used in a method of treating overweight and/or obesity by supporting a body weight control for at least 15 weeks in a patient having Type 1 diabetes and having a BMI of more than 28 kg/m2 and/or an HbA1c of more than 7.6%, and a method of treating Type 1 diabetes. The amylin receptor agonist may be a short-acting amylin receptor agonist such as pramlintide.
    Type: Application
    Filed: September 20, 2023
    Publication date: April 11, 2024
    Applicant: ADOCIA
    Inventor: Olivier SOULA
  • Publication number: 20240115664
    Abstract: Drug delivery systems have been developed based on the formation of diketopiperazine carboxylate salts and microparticles containing the same. The systems may further comprise a bioactive agent. Related methods for making and using the biologically active agent delivery compositions are also provided. In certain embodiments, the pharmaceutically acceptable salts described can be formed by removal of solvent by methods including distillation, evaporation, spray drying or lyophilization.
    Type: Application
    Filed: November 30, 2023
    Publication date: April 11, 2024
    Inventors: Andrea Leone-Bay, Destardi Moye-Sherman, Bryan R. Wison